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Abstract
An initiative to increase biopharmaceutical research productivity by capturing, sharing and
computationally integrating proprietary scientiﬁc discoveries with public knowledge is
described. This initiative involves both organisational process change and multiple
interoperating software systems. The software components rely on mutually supporting
integration techniques. These include a richly structured ontology, statistical analysis of
experimental data against stored conclusions, natural language processing of public literature,
secure document repositories with lightweight metadata, web services integration, enterprise
web portals and relational databases. This approach has already begun to increase scientiﬁc
productivity in our enterprise by creating an organisational memory (OM) of internal research
ﬁndings, accessible on the web. Through bringing together these components it has also been
possible to construct a very large and expanding repository of biological pathway information
linked to this repository of ﬁndings which is extremely useful in analysis of DNA microarray
data. This repository, in turn, enables our research paradigm to be shifted towards more
comprehensive systems-based understandings of drug action.
INTRODUCTION
Private companies undertaking
pharmaceutical research normally take
stringent measures to protect their
research results as private intellectual
property (IP), until they achieve a
marketable compound. An unintended
consequence of treating research as IP is
that many of the research teams within a
single company cannot effectively share
their research results with each other,
because they do not contribute to the
normal public academic discourse of peer-
reviewed journals and its accompanying
widely-available repositories of scientiﬁc
information. This public system, to which
they do not routinely contribute, is the
only system for widespread knowledge
dissemination available internally.
Pharmaceutical company researchers
are predominately consumers, rather than
suppliers, of content for the published
literature and its knowledge bases.
Consequently, while their peers in
academia and among commercial
competitors are blocked from access to
important proprietary discoveries, so are
their (non-competing) colleagues
elsewhere in the same company. Likewise
the company may lack an effective
historical memory of its research, outside
laboratory notebooks and personal
computer ﬁles, if it does not attempt to ﬁll
the gap left by opting out of public
discourse. We call this gap the ‘IP
shadow’, and we believe it creates scaling
limits to productivity in private
pharmaceutical research — possibly even
creating negative economies of scale
experienced as an ‘innovation deﬁcit’.1,2
The authors believe most
pharmaceutical company researchers can,
from their own experience, readily supply
examples of wasted effort, lost
opportunities and diminished productivity
at their companies, owing to inability to
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research ﬁndings across intra-company
organisational and geographical
boundaries. A systematic approach to
resolving these issues may become
increasingly vital in the context of
‘extended enterprises’, which now appear
to be the mode in the pharmaceutical
industry.3
This paper describes a comprehensive
initiative, MyBiology, designed to resolve
the problem of ‘IP shadow’ using
computational knowledge management,
lightweight process re-engineering and
web deployment. At the same time, this
initiative attempts to:
• create a more sophisticated
infrastructure than is currently available
to the public researcher;
• build in process design and process
adoption support from the beginning,
realising that adoption and use are
critical success factors; and
• develop advanced capabilities for
computational systems biology as part
of the infrastructure.
MyBiology deals, in part, with a version
of the ‘organisational memory’ (OM)
problem in knowledge management.
Previous OM efforts have been primarily
concerned with ‘business process’, that is,
with better recollection and dissemination
of how the enterprise does its work.
Ontology construction has been seen as
central to achieving this goal, which
in turn is presumed to inﬂuence
enterprise productivity and excellence of
product.4–6
Scientiﬁc knowledge in a
biopharmaceutical enterprise, however, is
itself a product. Therefore, managing this
knowledge is actually part of the
production process, and failure to manage
it properly contributes to wrong decisions
and attrition in the pharmaceutical
development pipeline.
MyBiology is a collaboration between
Millennium Pharmaceuticals and
Ingenuity Systems and is implemented at
Millennium across multiple research sites
on two continents. Initially focused
mainly on results relatively far ‘upstream’
in the research and development process,
it is rapidly being extended to have
productivity impact all the way to the
clinic. The system is described below and
results and prospects after one year of the
programme are assessed.
THE PUBLIC KNOWLEDGE
MANAGEMENT
INFRASTRUCTURE
Public academic researchers share
information and collaborate on a large
scale through the well-organised system of
peer-reviewed academic journals. Over
4,600 of these journals are continuously
indexed and organised into MEDLINE
17
by the US National Library of Medicine
using a formal ontology, the Medical
Subject Headings (MeSH1).8 This
constitutes a knowledge base (KB). Many
other databases have been linked to this
fundamental resource, including whole
genomes for various organisms of clinical
interest. These resources are readily
searchable on the web via PubMed
1
,9
providing a critical means of information
sharing for the scientiﬁc community.
Furthermore, there are numerous
computational methods available to
analyse research data, such as DNA
sequences, against the organised ﬁndings
of other researchers.10
Taken as a whole, these facilities
constitute an open, public framework for
scientiﬁc knowledge management. The
functionality of this framework must at
least be matched, if not bettered, within
private research organisations, to achieve
parity with public efforts in sharing
scientiﬁc knowledge.
The public framework is composed of:
• a peer-reviewed publication system;
• a knowledge base (MEDLINE);
• an ontology by which the KB is
organised (MeSH);
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(PubMed);
• computational methods for analysing
new research data against the KB;
• portals that collect search methods and
computational tools in a single site
(NCBI Entrez11);
• a transparent electronic framework
providing information accessibility,
identity and interoperability (internet,
W3C web protocols, registry
systems).12,13
As private companies choose to
replicate these elements, they must decide
whether to adopt the public technology
or to improve upon it. They also
encounter the challenge of creating ‘semi-
permeable’ links back to the public
system.
THE MYBIOLOGY
INITIATIVE
MyBiology was designed to eliminate the
‘IP shadow’ at Millennium and within
Millennium collaborations by:
• providing one or more curated internal
electronic journals of key research
results;
• extracting computable ﬁndings from
the internal journal into a KB founded
on a ‘deep’ ontology;
• integrating internal ﬁndings with
external public research using the same
ontology;
• analysing transcriptional proﬁling data
against biochemical pathways described
in the KB using novel algorithms;
• providing both text-based KB query
and graphical interface to pathway
analysis.
MyBiology integrates Millennium’s
proprietary information with information
from public literature to help scientists
build an evolving picture of complex
biological systems. As shown in Figure 1,
MyBiology consists of several related
components. Millennium scientists are an
integral part of MyBiology, both as
contributors and customers.
The major components of MyBiology
today are:
• an ontology;
• Millennium’s research scientists;
• knowledge intermediaries (KiMs);
• Journal of Millennium Science
( J. Mill.);
• external and internal databases;
• MyTargetValidation (MyTV);
• the Life Science Knowledge Base
(LSKB) and query interface;
• the public scientiﬁc literature;
• Pathway Analysis Research
Information System (PARIS).
An ontology is critical to organisation of
a KB, just as unique object identiﬁers and
foreign key relationships are fundamental
for various kinds of databases. Recent
work on scientiﬁc ontologies has
attempted to provide specialised
annotation and organisation for genomics
and genome-related research databases
(eg the Gene Ontology Consortium,
GO14) and computational service
classiﬁcation and organisation15 via
fundamental expressive formalisms
relevant for both purposes and suitable for
deployment on the internet.16
For our basic ontology, we selected a
system from Ingenuity Systems, Inc.,
together with annotated content, to
which signiﬁcant proprietary and in-
licensed content were added. The
Ingenuity ontology has many advantages,
among which are the ability to distinguish
Infrastructure
Semi-permeable links
Ontology
262 & HENRY STEWART PUBLICATIONS 1467-5463. BRIEFINGS IN BIOINFORMATICS. VOL 4. NO 3. 260–278. SEPTEMBER 2003
Ficenec et al.between objects and processes. The
resulting richly-connected KB means it is
possible, for example, to extract metabolic
and cell-signalling pathways automatically
and combine them with other
information sources for computational
analysis.
Research scientists are both providers and
consumers of information. They present
their experimental methods, results and
interpretations at regular research team
meetings throughout the company.
Finding ways to capture the information
in these presentations and to make it
readily available to scientists across the
company is a critical component of the
MyBiology effort.
Knowledge intermediaries work with
researchers to capture and encode the
information found in research scientists’
presentations. KiMs are PhD-trained
biologists and chemists with additional
training in computational science. The
system operates effectively with a very
small number of KiMs supporting more
than 1,000 researchers.
The Journal of Millennium Science is an
electronic journal constructed upon the
Documentum ECM Platform17 using
customised interfaces. Scientiﬁc
presentations, typically in PowerPoint, are
stored with metadata in J. Mill. Metadata
include an abstract, author and
publication information and unique
identiﬁers for targets, compounds or other
reagents referenced in the presentation.
MyTargetValidation is a scientiﬁc portal
to pertinent information on a given
biopharmaceutical target (gene/protein).
It integrates a large number of internal
and external databases using a Web
Services Architecture.18 It also enables
direct access to assay results in lead
optimisation for molecules active against a
target, through integration with an
internal drug discovery database of
compounds, assay results and basic
computed compound properties.
The Life Science Knowledge Base is a
highly-structured KB that combines
selected ﬁndings from the public literature
with internal Millennium research results
in computable form. Ingenuity employs a
large number of ‘content scientists’, to
read articles from 33 highly cited scientiﬁc
journals, curate the results and
interpretations, and add them to the KB.
They also use natural language processing
(NLP) to add information from
MEDLINE abstracts dating back to 1980.
The KB contains more than 1 million
ﬁndings, approximately 800,000 derived
by content scientists.
Lifesciences is a web-based application
from Ingenuity that provides textual
query access to the LSKB including a
comprehensive overview of all ﬁndings
related to a given gene, its products and
biological relationships.
The Pathway Analysis Research
Information System19 analyses the results of
a transcriptional proﬁling experiment
against the biological pathway
information in LSKB. It enables deeper
interpretation of cellular processes affected
in an experiment, by interpolating non-
transcriptionally regulated components of
relevant pathways.
Several stages of scientiﬁc research in
support of pharmaceutical discovery and
development are supported by these
components. For example, target
identiﬁcation and validation are enabled
Repository
Experimental ﬁndings
Encoding
Computation
Information Sources
(Millennium and External)
My TV
Scientists
Scientific
Presentations
Knowledge
Intermediaries (KiMs)
J. Mill
Paris IngenuityTM Millennium®
Life Science Knowledge Base
(SKB)
LSKB Application
External
Publications
Figure 1: The MyBiology system at a high level component view
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researchers evaluate results from genome-
scale experiments and seek to better
understand the role that individual genes
and their products play in the system
under study. In characterising individual
compounds, PARIS is often used better
to understand the mechanism of action of
the chemical, as it provides important
context to understanding the large
numbers of genes that are typically
affected in a single experiment. The
PARIS pathway browser is further used
to explore the interconnections between
proteins identiﬁed in an experiment.
Furthermore, there has been great
value in extending J. Mill. into areas
outside biology; several different groups
of researchers have approached the KiMs
about including reports and other
scientiﬁc results in J. Mill. so that they are
more broadly available and are integrated
with the rest of the Millennium
knowledge integration platform. PARIS
is having a dramatic impact on the analysis
of clinical trial data in the form of
evaluating patient responses to candidate
pharmaceuticals. Through its pathway
mapping and interpretation, it provides
analysts with context sufﬁcient to direct
further research experiments in support of
the therapeutic goal.
The most fundamental goals of this
initiative are to enable scientists to employ
all available scientiﬁc information —
public and private; to select targets and
compounds most likely to succeed in
clinical development; and to conduct
more effective clinical trials. Ultimately,
we wish to shift our research paradigm
away from a dyadic compound ! target
view and towards a more holistic
compound ! pathway ! disease
understanding. Increases in productivity
here should result in faster availability of
improved therapies to patients.
MYTARGETVALIDATION
Researchers seeking to understand the
biology of a system under study seek
information from many sources, including
public literature and external websites
with information on gene and protein
families (eg NCBI20 and GO). Also,
researchers at Millennium have typically
interacted with core technology groups
via the web to request experiments and/
or access the results. This led to a
proliferation of individual unconnected
websites and to redundant requests for
identical experiments from different
researchers. Researchers expressed
enthusiasm for a single point of entry for
access to multiple sources of information
from both external sources and internal
resources.
MyTV is a scientiﬁc portal (see Figure
2) to all available information on a given
target, whether external or internal. It
begins to answer the question: ‘What do
we know about this target?’
Access to information in MyTV is
valuable in many different contexts of
pharmaceutical development including
target discovery, target validation, assay
development, lead optimisation and
analysis of clinical data. At a glance, a
scientist can quickly assess what research
has been performed at Millennium, by
whom and in what stage of the pipeline;
what types of experimental data are
available; and what information is
available from the public domain
regarding biological targets and their
annotation.
Public information is acquired through
mappings to identiﬁers provided by
Millennium’s Gene Catalog system — a
non-redundant catalogue of all genes
constructed from both public and
proprietary DNA sequences and
annotations. Public sources include:
SWISS-PROT,21 LocusLink,22,23
OMIM,24 GO, InterPro25 and
ENZYME.26 MyTV also links targets to
Ingenuity’s LifeSciences GeneView,
providing access to key ﬁndings from the
public literature and internal ﬁndings
captured in J. Mill. and curated into
Ingenuity’s KB.
Millennium’s other internal sources
include:
• GeneCatalog for information on
PARIS
Integration
Target validation
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chromosome location and orthologues.
• Reagents and experimental systems that
include information on expression
vectors, expressed proteins, micro-
arrays and experiments done in
molecular pathology including TaqEE,
a warehouse of TaqMan expression
data.
• Scientists’ analysis and interpretations
are surfaced through links to Synopsis, a
system for capturing interesting sets of
genes and their biological context;
J. Mill. for key scientiﬁc presentations
and ﬁndings; summary reports from the
Target Advancement and Assay
Development groups.
• MyDrugDiscovery, Millennium’s
portal for information on high-
throughput screening of targets and
other assay information about
compounds and lead series.
MyTV uses a pull model to query
multiple systems for summary information
about each target. Each system to be
queried implements a simple web service
returning an XML27 fragment adhering to
the MyTV XML schema.28 The system
then constructs an XML ﬁle for each
target. This XML content is transformed
into HTML29 by the presentation layer.
The system uses on-demand
instantiation: target content is not
aggregated until a scientist requests it. All
requested information is then cached on
the ﬁle system. Cache is periodically
updated to refresh the information.
The system was initially released in a
basic conﬁguration in May 2002.
Frequent releases were made, integrating
new systems as requested, adding
signiﬁcant functionality over time, and
continuously improving performance.
Within four months, MyTV developed a
user base of over 100 scientists. On a
typical day, 20–25 individuals use the
system. After about ﬁve months of use,
users were surveyed to assess their
perception of MyTV’s impact on their
work. Scientists strongly agreed that the
system improved their productivity (they
spend less time ﬁnding information) and
quality of decision making by providing
more complete and relevant information.
JOURNAL OF MILLENNIUM
SCIENCE
J. Mill. is a collection of software,
processes and semi-structured data. It
serves as a central repository of
experimental results and interpretations.
J. Mill. is designed to maximise the
connectedness of research teams across
Content aggregation
Caching
Productivity
Web services
Figure 2: Example
MyTV page for DNA
topoisomerase I
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organisational memory of key scientiﬁc
ﬁndings with links to supporting data and
serve as a staging area for ﬁndings export
to the highly structured KB. It was
considered helpful to use a framework
similar to one that researchers are familiar
with, that of publication in a scientiﬁc
journal.
J. Mill. relies on the fact that most
scientiﬁc communication occurs in a
group setting and is supported by
electronic documents such as
PowerPoint30 presentations containing
scientiﬁc results and interpretations. Since
these documents form the core of the
communication between scientists on a
project team, if they were archived with
some associated metadata, a record would
be available of the important activities
undertaken by the project team.
By providing a central location for
scientiﬁc results, it was hoped to
encourage information sharing and reuse
among Millennium scientists and to
prevent critical information from being
lost or overlooked. J. Mill. is accessed via
a web-based application which allows
scientists to browse the repository and
KiMs to publish entries in the repository.
Published J. Mill. entries are also available
through MyTV.
An entry consists of documents
describing an internal Millennium
presentation and curated metadata about
that presentation. The documents are
typically Microsoft Word31 or
PowerPoint ﬁles that have been presented
within Millennium along with metadata
about the presentation curated by a
Millennium scientist. The metadata
include information such as the author,
gene and compound names and identiﬁers
and some key scientiﬁc ﬁndings distilled
from the presentations.
J. Mill. application
The J. Mill. application is a three-tier web
application. Its user interface for browsing
is deliberately reminiscent of PubMed,
with which scientists are already familiar.
J. Mill. is written in Java and uses the
Documentum Foundation Classes
(DFCs)32 to access Documentum’s
eContent Server, which stores J. Mill.
documents and presentation metadata and
manages the document life cycle. In
addition, several open source frameworks
and components are used, including
Jakarta’s Struts33 which enforces a model–
view–controller (MVC)34 architecture
within the application. The presentation
layer is written using JavaServer Pages
(JSPs)35 and the Struts tag libraries to
format the presentation for the user.
Authentication of users is accomplished
via a web-based single-sign-on (SSO)
web agent.
J. Mill. makes itself available to other
applications through the publication of a
simple object access protocol36 (SOAP)
interface that allows other applications to
execute queries against J. Mill. content.
The SOAP interface requires the same
user authentication as the web application
and uses the same SSO interface to
control access.
J. Mill. was initially put into production
in June 2002. Since that time,
approximately 100 articles by Millennium
authors have been published internally. In
the future, J. Mill. will provide self-
publication facilities to authors in order to
expand its ability to collect and publish
content more rapidly to our scientists.
LIFESCIENCES FOR
MILLENNIUM
The Ingenuity LifeSciences Suite (Figure
3) is a user interface to the Ingenuity
Pathways KB. It includes GeneView,
which catalogues the functions of a given
gene and gives scientists access to
functional assertions between a speciﬁc
gene and other genes, small molecules and
cellular processes (Figure 3), as well as the
speciﬁc biological experiments supporting
each assertion. Most features of
GeneView run dynamically off the KB;
for example, statements regarding
biological experiments are generated
using natural language algorithms applied
to structured information stored in the
knowledge server. Each new piece of
Documentum#
Scientiﬁc
communication
Repository
Metadata
GeneView
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relevant ﬁndings in the KB.
Alternatively, scientists using the Query
application may pose a speciﬁc question
regarding relationships between biological
entities; for example, ‘What apoptotic
effects does cytochrome c exert in
neurons?’ The ﬁelds in Query, which
reﬂect the perturbations and results
recorded in most biological experiments,
enable scientists to construct these
questions efﬁciently and intuitively.
Query intelligently leverages the
underlying ontology to empower the
biologist: for example, a query about
neurons returns ﬁndings regarding
superior cervical ganglion cells, as the
ontology recognises the ganglion cells as a
type of neuron (Figure 4).
Two methods are used to capture
ﬁndings. In ﬁndings capture through
expert knowledge acquisition, quality-
controlled operational processes enable
Ingenuity-trained, PhD-level scientists to
structure information from full text
articles with a high degree of semantic
richness. This method was applied to tens
of thousands of articles from the most
highly cited biological journals. The
second method, semi-automated
knowledge acquisition, employs
algorithmic capture of knowledge from
the abstracts of hundreds of journals
spanning more than a decade of published
research. In both approaches, every
ﬁnding structured into the Ingenuity KB
was quality-checked by a PhD-level
scientist.
KB Query
Findings
Figure 3: A GeneView page displaying relationship between Xpo1 and Ran provides the user with a natural language
display of the underlying relationships and properties of that object, shown here. Note that ﬁndings were also returned
containing the ‘Crm1’ synonym of Xpo1. This synonym capability resides in the Ingenuity ontology
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THE MYBIOLOGY KB
To build a platform for biological
computation — as well as for intelligent
search and query — it was thought
necessary to integrate the large corpus of
literature-based ﬁndings in the Ingenuity
KB with key experimental results from
Millennium’s research programmes into a
single, computable structure. This posed
multiple challenges; for example, semantic
inconsistency in the literature makes it
difﬁcult to recognise when genes are
identical or distinct. A need for a high
degree of accuracy impedes the rate at
which experimental ﬁndings can be
formally represented. Finally, more
sophisticated computations will probably
require detailed context regarding
functional relationships — for example, in
what cell type one protein phosphorylates
another.
Frame-based knowledge representation
systems offer a versatile and powerful
approach to structuring knowledge while
addressing these critical needs. Generally,
frame-based systems allow deﬁnition of
abstract concepts and their relationships
with other concepts.37 These systems
deﬁne three types of formal objects to
represent knowledge in a given domain:
concepts, properties and instances.
Concepts (classes) are descriptions of
particular categories of objects. Properties
are attributes that describe the concept
itself or relate one concept to another. An
instance is a real-world example of a
concept. Once information is represented
in this manner, most frame-based
knowledge representation systems support
Frame-system
Figure 4: Query result after search for apoptotic effects of cytochrome C on neurons. Note that superior cervical
ganglion neurons were recognised as a type of neuron
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classiﬁcation (‘Is this protein a type of
kinase?’) and declaration of axioms (‘If
loss-of-function mutations in a gene lead
to a DNA repair phenotype, that gene
participates in DNA repair’). Axioms in
particular impose semantic constraints on
the KB that help maintain the consistency
and integrity of the data. Finally, frame-
based knowledge representation systems
provide basic query capabilities for
retrieving stored data.
Using a frame-based knowledge
representation, one can build an ontology
(Figure 5): a taxonomy and formal
description of the concepts and
relationships germane to a particular
domain. Ontologies can be used in many
different ways. By deﬁning a class
structure and formalising relationships
between those classes, ontologies (i) allow
more efﬁcient browsing of concepts
through the taxonomy, (ii) provide a
standard framework for exchange of data,
and (iii) provide the basis for representing
domain knowledge. Building the
ontology for a frame-based system is
analogous to building the schema for a
relational database. A KB consists of an
ontology populated with instances of real
data. In academia, frame-based
representations of biological data have
proven useful in several biological
domains across a range of organisms.38–41
Ingenuity has developed a frame-based
system with the goal of representing
hundreds of thousands of functional
relationships between genes for the
purpose of enabling computations that
provide critical path insights to scientists
involved in therapeutic discovery.
Toward this end, Ingenuity has
constructed a proprietary ontology of
more than 300,000 distinct classes
including, but not restricted to, genes
proteins, small molecules, cellular
Biological ontology
Figure 5: A conceptual model showing how a biological ﬁnding is formally represented in the Ingenuity Pathways KB using
objects structured to capture meaning and context from the scientiﬁc experiment. Actual ﬁndings contain more semantic
detail than displayed here, and the actual ontology is composed of more than 300,000 classes
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processes. Ingenuity has utilised this
ontology to formally represent, in
machine computable form, more than a
million biological experimental ﬁndings
from the public domain literature,
speciﬁcally focused on human, mouse and
rat genes. The Ingenuity KB can be used
to structure not only knowledge from the
public domain, but also a pharmaceutical
organisation’s proprietary scientiﬁc
ﬁndings, creating a leveraged, integrated
knowledge asset. This project has
required scalability for both the ontology
and the back-end not previously
demonstrated in the smaller, academic
efforts at frame-based systems described
above. Ingenuity currently has operational
processes capable of incorporating, per
month, more than 5,000–10,000
concepts into its proprietary ontology,
and more than 40,000 biological ﬁndings
into the KB.
Applications have been developed to
leverage the Ingenuity KB in support of a
diverse array of computations, enabling
the discovery process for end-user
biologists — including both systems
biology computations producing
sophisticated pathway predictions from
genomic data — and access to the
underlying knowledge (LifeSciences
applications, above). Also, the KB enables
internal bioinformatics organisations to
integrate proprietary information and use
the combined resource to innovate new
solutions. Both avenues were taken in
supporting the MyBiology initiative.
PROCESS INTEGRATION:
THE SCIENTIFIC FINDINGS
CAPTURE PROCESS
If the goal of the MyBiology KB was
semantic integration — exploiting the
Ingenuity system’s ‘knowledge’ of
biological concepts and relationships to
enable intelligent query and computation
— then an equally important goal was
process integration. By process integration
is meant the ability to integrate or embed
the use of the KB into Millennium’s
research processes. Speciﬁcally, a means of
capturing and curating Millennium’s
internal research results for entry into the
KB was needed. The challenge, of course,
lay in the various forms that such results
may take in a modern pharmaceutical
company (notebook entries, annotated
gene lists, PowerPoint presentations,
etc.).
In approaching this problem, the
premise was that demands may only be
made on scientists (eg to contribute
scientiﬁc ﬁndings to an electronic
repository) in proportion to the value
they perceive from using the system. The
‘bootstrapping’ problem was how to get
scientists to contribute as ‘producers’ of
knowledge before there existed a critical
mass of content within the repository for
them to draw upon as ‘consumers.’ As an
initial strategy, a small number of
dedicated ‘curation’ roles were created in
order to initially minimise the burden of
participation upon scientists. These
dedicated roles are currently being moved
away from.
SCIENTIFIC FINDINGS
CAPTURE
The scientiﬁc ﬁndings capture (SFC)
process was developed as a systematic
method for capturing presentations and
their associated ﬁndings for publication
Millennium-wide in both J. Mill. and the
Ingenuity LSKB. The process is
composed of several discrete steps and
metrics gathering has been incorporated
throughout. Initially, this work was
started with the dedicated support of
KiMs. KiMs served to assist individual
research scientists with the process of
knowledge sharing.42 SFC KiMs were
PhD scientists with knowledge of the
internal and external computational tools
used by Millennium scientists. SFC has
several steps, which are outlined below.
Encoding the presentation
Scientists serving as KiMs are invited to
laboratory and departmental meetings
where scientists present the results of their
work to their colleagues. These
presentations are typically prepared in
Experimental ﬁndings
Scalability
Findings capture
Pathway predictions
Process integration
270 & HENRY STEWART PUBLICATIONS 1467-5463. BRIEFINGS IN BIOINFORMATICS. VOL 4. NO 3. 260–278. SEPTEMBER 2003
Ficenec et al.PowerPoint and are excellent sources of
key experimental results and
interpretations. Using the J. Mill. web
application (see above), an individual
laboratory scientist’s presentation is
separated into components resembling a
journal article. A title and abstract are
prepared using background material, and
hyperlinks to internal and external
resources are also included within the
application.
Publication
After initial creation in J. Mill., the
completed entry is returned via e-mail to
the presenting scientist for ﬁnal approval.
In this manner, the role of the presenting
scientist is similar to that of the author of a
scientiﬁc manuscript in that he/she is
ultimately responsible for its contents.
Upon approval, the presentation is
automatically published Millennium-wide
through MyTV.
TRANSFERRING
EXPERIMENTAL RESULTS
FROM MILLENNIUM TO
INGENUITY
To generate a combined KB of internal
Millennium content and external
Ingenuity content, a transfer system was
devised to facilitate the transfer of
Millennium experimental results (MERs)
to a private copy of the Ingenuity KB.
All scientiﬁc presentations contain
potential MERs to be represented in the
Ingenuity KB. Those ﬁndings determined
to be useful in the KB are queued for
entry. All proposed novel terms and genes
are examined and validated by both teams
to verify accuracy. Also, clariﬁcation of
ﬁndings from the KiMs is a necessity to
ensure that the translation from the
written sentence in J. Mill. to the
Ingenuity KB is performed consistently.
Each MER is modelled into the Ingenuity
ontology by the Ingenuity content
scientists and displayed in LifeSciences
within the context of the ﬁndings derived
from the external literature. Further, a
hyperlink to the original presentation in J.
Mill. is also available for easy reference as
well as increased searchability through
Ingenuity’s LifeSciences Query
application.
TECHNICAL
INTEGRATION: THE
MYBIOLOGY
ARCHITECTURE
A third but equally important aspect of
integration in the MyBiology project was
the technical integration of MyTV,
J. Mill. and the MyBiology KB into
Millennium’s informatics platform within
a coherent architecture, despite the rather
complex technical environment.
The hardware and network for
deployment were primarily Millennium’s
internal network but there was also a need
to include some form of connectivity to
the Ingenuity LSKB and Ingenuity’s
LifeSciences application. End-users used
both Microsoft Windows and Apple
Macintosh computers.
The MyBiology software environment
included four applications (MyTV,
PARIS, LifeSciences and J. Mill.). These
applications had to be able to link to
several other existing web-based
applications. Each of the applications,
existing and new, was targeted at different
user communities and had been
customised for their use.
Within this context, we also had the
following requirements for the MyBiology
architecture:
• User experience. Users must have a
common user experience when using
any of the MyBiology suite of
applications, and it must be easy to
navigate between applications.
• User access. The applications need to
be accessible from both Microsoft and
Macintosh computing platforms.
• Decoupled development.
Asynchronous releases across the four
development teams improved
productivity.
Integration
Electronic publication
Architecture
Knowledge transfer
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MODEL AND DISCUSSION
To make transitions between applications
seamless, the MyBiology software
architecture (Figure 6) focused on the
interconnections and transitions between
the applications. To maintain loose
coupling between the applications and
databases, connections to application
databases were limited solely to the
applications that owned them.
Connections between the applications are
permitted at two levels. Low-level
connections were made between
applications using web services. User
interface level connections were made
between applications via HTML links. At
the lower level, application-to-application
connections were made using web
services via the SOAP interface. A single
standardised SOAP interface was exposed
by all applications. These SOAP
connections were used to pass data
between the applications and to provide
URL links that the client application then
used to provide links between the
applications at the user interface level.
These SOAP connections were also used
to connect to other applications outside
the MyBiology initiative.
The exception to this form of
connectivity is the LifeSciences
application. In this case, since the
application was hosted outside
Millennium, the applications are
connected via periodic ﬁle transfers, over
a secure network, of the data to be shared
with Ingenuity’s KB and the links back to
the Millennium applications.
The architectural approach used in
MyBiology has been successful in its
primary goals of preserving loose coupling
between the applications for ease of
development while simultaneously
presenting a uniﬁed seamless view of the
applications to the end users.
THE PATHWAY ANALYSIS
AND RESOURCE
INFORMATION SYSTEM
The IngenuityKBintegrates large
amounts ofbiological knowledge.Because
thisinformation isencodedin astructured
format thatenables computation,the
Ingenuity KBcanbe usedto solve oneof
the more difﬁcult challenges indrug
discovery:the identiﬁcationof the
intracellular processesperturbedor
activated inabiological experiment.
The PARIS database of protein
functional relationship integrates data
Figure 6: The MyBiology
architectural model
272 & HENRY STEWART PUBLICATIONS 1467-5463. BRIEFINGS IN BIOINFORMATICS. VOL 4. NO 3. 260–278. SEPTEMBER 2003
Ficenec et al.from both public sources (CSNDB,43
LIGAND44) and the Ingenuity KB,
including Millennium scientiﬁc ﬁndings
encoded in the KB. This integration has
given Millennium a human pathway
database much larger than any publicly-
available resource.
The detection of perturbed pathways is
required to understand the function of a
novel gene, the mechanism of action of a
compound or the different responses of
patients to treatment. Transcript proﬁling
(TP) using microarrays is a powerful
technology to perform such
investigations: in a single assay the
transcriptional activity of the entire
genome can be measured.45
Translating hundreds of observed
mRNA changes in terms of perturbed
pathways is work too complex to be
optimally performed by hand, however.
Help can be provided to the researcher by
using computation.46,47 Such
computation combines the experimental
data with large amounts of pathway
knowledge and extracts the portion of the
knowledge relevant to the observed
transcriptional activity. Besides helping
the scientist deal with large amounts of
data, appropriate computation can also
signiﬁcantly improve the sensitivity of TP
data interpretation. Indeed, it is now well
established that functionally-related genes,
eg pathway neighbours, have a signiﬁcant
tendency to be simultaneously regulated
at the mRNA level.48–50 Therefore, even
if the individual gene expressions stand in
the range of experimental noise, the
coordinated differential expression of
genes belonging to a same pathway can
indicate its perturbation.
Computational interpretation of TP
data requires large quantities of pathway
knowledge. The coverage provided by
current public sources51,52 is relatively
low. Moreover, to enable computation
the data have to be consolidated into one
format. The Ingenuity KB is an ideal
source of pathway knowledge.
Consequently, Millennium uses
Ingenuity to maintain a system called the
Pathway Resource and Information
System (PARIS). The knowledge
contained in PARIS can be summarised
in a graph where vertices are genes and
edges represent their functional
relationships (Figure 7). Those
relationships are: membership in the same
complex, protein binding, post-
translational modiﬁcations, transcriptional
regulation and neighbouring of enzymes
in metabolic pathways. Currently the
network contains about 5,000 genes and
22,000 interactions.
Millennium’s computational biologists
have developed algorithms that use this
network to analyse TP experiments.19
The algorithms identify the portions of
the graph that are signiﬁcantly regulated
in a given experiment (Figure 8). For
each gene the average regulation in its
pathway neighbourhood is computed.
This local density of transcriptional
activity is then compared with those
obtained when randomly reassigning the
individual gene expressions.
Figure 8 shows an example of
application of the PARIS system to
identify pathways perturbed upon p53
mutation in ovarian tumour samples.53
The PARIS system has extracted a set of
genes having signiﬁcant density of
differential expression in their functional
neighbourhood when comparing
transcript proﬁling of p53 null samples
against p53 wild-type samples. Those
genes deﬁne pathways related to cell cycle
and proliferation, tumour growth factor
beta signalling and cellular adhesion.
The PARIS system, based on pathway
knowledge extracted from the Ingenuity
KB, is used at Millennium to analyse TP
experiments performed at several stages of
the drug discovery process. The
computationally extracted pathways can
point to the cellular processes downstream
of a target, which are perturbed by a
compound, responsible for drug resistance
or involved in the different responses of
patients to treatment.
The PARIS web application contains
hyperlinks to MyTV and other sources to
enable scientists to rapidly learn about
genes regulated in their experiments.
Graph
Pathway database
Microarray
Neighbourhood
Regulation
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Biopharmaceutical-scientiﬁc knowledge is
acquired through a long and expensive
series of directed experiments, in which
the supporting data can become quite
voluminous. New experimental data must
be posited against the conclusions from
previous experiments. Integration and
synthesis with public knowledge must be
complete, but knowledge developed
inside the enterprise must remain shielded
so long as it is treated as intellectual
property. Keeping knowledge hidden
from competitors may result in it being
hidden from the broader organisation.
Our goal was to resolve these problems
using a suite of technologies and
organisational process change.
What was achieved? The system
described in this paper is currently in
production at Millennium and is being
actively extended. It provides not only a
long-term organisational memory for
key science in the biopharmaceutical
enterprise, with enhanced analytical
capability for experimental data, but also
the fullest record of inter-linked data
and information to enable more
informed decisions about the project
pipeline.
Experiences with this system to date
show that:
(1) The semi-structured and lightweight
J. Mill. KB is much more signiﬁcant
than was originally thought.
(2) The availability of public domain,
highly structured ﬁndings provides
substantial value even in the absence
of internal experimental results.
(3) The ability to directly posit
experimental data from transcriptional
proﬁling upon the Ingenuity KB is
extremely productive and has led to
Decisions
Transcript proﬁling
Figure 7: Interpretation of transcript proﬁling experiments using the PARIS system. Knowledge extracted from the
Ingenuity knowledge base is represented as a simple undirected graph where vertices are genes and edges represent their
interactions (eg binding). During a TP experiment analysis, each gene of the graph is scored for the density of differential
expression observed in its neighbourhood. Genes at the centre of signiﬁcantly regulated neighbourhoods (eg P , 0.05)
induce a subgraph representing the regulated pathways
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mechanisms of action.
(4) It is important to direct the content
acquisition of the KB, and to align it
with the research.
J. Mill. was originally conceived mainly
as a staging area for capture of the highly
structured ﬁndings. As it turns out, it has
become valuable in its own right as a
primary repository for enterprise research
ﬁndings in human-readable form. This is
due both to the rich context provided by
the underlying presentations and to the
familiar PubMed usage pattern where
scientists can skim a title and abstract
before going to the original source
material. While Ingenuity’s highly
structured KB is invaluable for
computation, links to the original source
material (both J. Mill. and public sources)
provide critical additional background and
context vital to correct interpretation.
The linkage from MyTV to J. Mill. also
contributed to the effective use of J. Mill.
and proved to be highly beneﬁcial for
gaining new insight into future
experiments. One example case occurred
when a scientist reviewing target
information in MyTV encountered a link
to related experiments in J. Mill.A n
examination of the presentation led to a
change in future experimental design and
a potential new research avenue.
The ability to capture and structure
Semi-structured
ﬁndings
Insight
Figure 8: PARIS analysis of p53 null v. wild-type clinical ovarian tumours.53 The graph shows
the pathways that were computationally extracted using the PARIS system when comparing
p53 null ovarian tumour samples with tumour samples that have not lost p53. Each gene is
represented by a square whose size and shade reﬂects the differential expression between
groups of tumours. Dark grey means more expression in p53 null samples and light grey less
expression. A line between two genes indicates the existence in the PARIS system of a
functional relationship (eg binding) between their products. The position of the genes on the
picture tries to preserve their respective distances in the full network
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important, because proper structure
allows computation across a very large
corpus of knowledge. At present our
internally generated knowledge
constitutes only a tiny fraction of the KB
— consequently most of its
computational power comes from public
knowledge, as expressed in the formal
language of the KB’s ontology. In this
context, its single most valuable
application has been found to be in
combination with the PARIS algorithms,
in analysing transcriptional proﬁling
experiments. In part, this is a reﬂection of
the state of experimental technology and
the power of genome-scale expression
analysis. We conclude that the most useful
knowledge currently going into the KB is
therefore that concerning pathways.
Accordingly we have accelerated our
work in capturing pathway-related
ﬁndings from public literature and
databases.
Unlike browsing by humans,
computational approaches can leverage
the consistency, structure and quantity of
information in the knowledge base. The
PARIS approach has proven successful
because it enables scientists to apply this
prior knowledge to genome-scale
expression data and quickly gain insight
into biological processes relevant to the
experimental context. It is expected that
PARIS will be the ﬁrst of many
computational approaches that will be
able to exploit Ingenuity’s KB.
The value of computational pathways
analysis is increased by its broad
application across the pharmaceutical
pipeline:
• In the area of target discovery, analysis
of model systems and their
perturbations was enabled our scientists
to identify new pathways containing
potential therapeutic targets. The
relevance of these pathways was not
anticipated and represents new
knowledge about the biology of the
model systems.
• For compounds that are in-licensed for
further development, pathway analysis
has proven to be valuable for validating
and exploring the supposed
mechanisms of these compounds. For
one compound, the analysis suggested a
different mechanism of action — one
that had a more favourable competitive
landscape.
• Applying pathway analysis to our
clinical data has provided valuable
insights into the molecular differences
between responders and non-
responders and suggested biologically
relevant signatures for distinguishing
the two populations. This is being used
to guide development of follow-on
compounds and biomarkers for
pharmacogenomics.
Lastly, it is vitally important in such a
system to direct the content acquisition
and to establish control and feedback
mechanisms. If the process and software
systems are working, proper direction and
feedback will advance the scientiﬁc
understanding and this will be perceptible
by the scientiﬁc staff and management.
Better operational decision-making will
be enabled, and this in turn should be
captured.
A record of operational decisions
should complement scientiﬁc knowledge
and deserves an equal place in the
organisational memory. There are never
enough resources to do all the desired
experiments. Operational knowledge in
this context really concerns scientiﬁc
judgments in the context of limited
resources. Future versions of MyBiology
will begin to capture such higher-level
decisions affecting the entire drug
discovery pipeline within the enterprise.
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